This implies that passive immunization with tau antibodies is usually a viable therapeutic goal and the CSF volume of p-tau262/356 or from the microtubule binding domain (MTBD) can serve as a practical biomarker of tau pathology to watch tau therapeutics in scientific trials.First, they examined this process on eighteen set up biosensor strains tha